New PET tracer could spot hidden fungal infections
NCT ID NCT07704333
First seen Jul 15, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This Phase 1 trial tests a new radioactive tracer called [18F]-Fluorocellobiose ([18F]FCB) for PET/CT scans. The goal is to see if it can help find invasive mold infections in the body. The study includes healthy volunteers and people with known fungal infections. Participants receive the tracer through an IV and undergo imaging to measure how it travels through the body and collects at infection sites.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a radioactive tracer called [18F]-Fluorocellobiose ([18F]FCB) for PET/CT scans
- What this could lead to
- If successful, this could provide a new way to detect fungal infections in the body using imaging scans, potentially leading to earlier diagnosis and treatment.
- What could go wrong
- This is an early Phase 1 trial focused on safety and imaging properties, not on treatment outcomes. The tracer may not reliably distinguish infections from other conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPERGILLOS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
- Hospital study tracks deadly fungus and a possible predictor of patient outcomes
- Can a cancer drug wake up immune cells to beat HIV-Related infections?
- Cresemba under the microscope: Real-World safety check for fungal infections
- Real-World study examines Isavuconazole's effectiveness against deadly fungal infections
- New hope against deadly fungus: phase 3 trial launched